Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Cancer Res. 2018 Mar 12;78(11):3002–3013. doi: 10.1158/0008-5472.CAN-17-2433

Figure 6.

Figure 6

Expression of either AXL and/or PROS1 were clinically associated with a poor prognosis for GBM patients. A. Kaplan-Meier curve showing patient survival data (TCGA data) stratified based on AXL and PROS1 expression levels. Patients expressing lower levels of AXL survived for a significantly longer period than those expressing higher levels (upper left). Patients expressing lower levels of PROS1 survived for a significantly longer period than those expressing higher levels (upper right). Patients expressing lower levels of both AXL and PROS1 survived longer than other groups (lower left). Statistical analysis was performed with a log-rank test (P < 0.05). B. Schematic representation of the effects of BGB324 treatment on GBM. Tumor-associated macrophages produce PROS1, which binds to AXL resulting in AXL phosphorylation and activation. Downstream targets of AXL, such as NF-κB, are activated, leading to expression of PD-L1 and subsequent cell growth. These events are inhibited by BGB324 treatment.